It is believed that estrogen deficiency contributes importantly to the pathogenesis of menopausal metabolic syndrome and symptoms can be ameliorated with estradiol therapy. The present study reports efficacy of 17-β estradiol encapsulated nanoparticles in treating the postmenopausal dyslipidemic condition. Estradiol encapsulated poly(lactide-co-glycolide) (PLGA) nanoparticles were prepared by emulsion-diffusion-evaporation method and evaluated in estrogen deficient (ovariectomized) high fat diet induced hyperlipidemic rat model. The results obtained showed that estradiol nanoparticles were equally/more effective in treatment of estrogen deficient hyperlipidemic conditions at three times reduced dose and frequency in comparison to that of drug suspension administered orally. Together, these results demonstrate the ability of nanoparticles in improving oral bioavailability/efficacy of estradiol.
- estrogen therapy
- lipid profile
- oral drug delivery
Mittal, G., Chandraiah, G., Ramarao, P., & Kumar, M. N. V. R. (2008). Pharmacodynamic evaluation of oral estradiol nanoparticles in estrogen deficient (ovariectomized) high-fat diet induced hyperlipidemic female rat model. Pharmaceutical Research, 26(1), 218-223. https://doi.org/10.1007/s11095-008-9725-x